<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00358371</url>
  </required_header>
  <id_info>
    <org_study_id>103811</org_study_id>
    <nct_id>NCT00358371</nct_id>
  </id_info>
  <brief_title>Bioavailability Of Flucloxacillin Capsules (250 mg and 500 mg)</brief_title>
  <official_title>A Mono-center, Open, Randomized, Three-way, Twelve-sequence, Cross-over Study to Determine the Extent of Absorption (Absolute Bioavailability), Rate of Absorption and to Further Characterize Distribution and Elimination Characteristics of a Commercial 250 mg and a 500 mg Capsule of Flucloxacillin Each Given as a Single Oral Dose vs. One 250 or 500 mg Intravenous Dose to 24 Healthy Male and/or Female Subjects in the Fasting State</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <brief_summary>
    <textblock>
      Primary objective:To study the absolute bioavailability, distribution and elimination&#xD;
      parameters of flucloxacillin from two oral formulations of flucloxacillin in healthy male&#xD;
      and/or female subjects.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A mono-center, open, randomized, three-way, twelve-sequence, cross-over study to determine&#xD;
      the extent of absorption (absolute bioavailability), rate of absorption and to further&#xD;
      characterize distribution and elimination characteristics of a commercial 250 mg and a 500 mg&#xD;
      capsule of flucloxacillin each given as a single oral dose vs. one 250 or 500 mg intravenous&#xD;
      dose to 24 healthy male and/or female subjects in the fasting state&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 6, 2005</start_date>
  <completion_date type="Actual">February 8, 2005</completion_date>
  <primary_completion_date type="Actual">February 8, 2005</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Absolute (Abs.) bioavailability, max. plasma conc., concentration-time curve (AUC) from 0 hto the last quantifiable conc., AUC from 0 h to infinity), timepoint of max. plasma conc., Halflife of drug elimination during the terminal phase</measure>
    <time_frame>Up to 60 Days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Elimination rate constant, total Clearance, Volume of distribution at steady state, Volume of distribution during the terminal phase, residual area</measure>
    <time_frame>Up to 60 Days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Infections, Bacterial</condition>
  <arm_group>
    <arm_group_label>Subjects receiving flucloxacillin 250 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will be randomized to receive single oral dose of 250 mg flucloxacillin capsule and 250 mg Intravenous dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Subjects receiving flucloxacillin 500 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will be randomized to receive single oral dose of 500 mg flucloxacillin capsule and 500 mg Intravenous dose</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>flucloxacillin 250 mg</intervention_name>
    <description>Subjects will be randomized to receive single oral dose of 250 mg flucloxacillin capsule and 250 mg Intravenous dose</description>
    <arm_group_label>Subjects receiving flucloxacillin 250 mg</arm_group_label>
    <other_name>flucloxacillin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>flucloxacillin 500 mg</intervention_name>
    <description>Subjects will be randomized to receive single oral dose of 500 mg flucloxacillin capsule and 500 mg Intravenous dose</description>
    <arm_group_label>Subjects receiving flucloxacillin 500 mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy volunteers,&#xD;
&#xD;
          -  Caucasians,&#xD;
&#xD;
          -  Body Mass Index (BMI) between 19 and 27 kg/m 2;&#xD;
&#xD;
          -  physically and mentally healthy as judged by means of a medical and standard lab&#xD;
             examination;&#xD;
&#xD;
          -  non-smokers,&#xD;
&#xD;
          -  ex-smokers or moderate smoker.&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          -  medical history,&#xD;
&#xD;
          -  vital signs,&#xD;
&#xD;
          -  physical examination,laboratory tests (blood and/or urine) with evidence of clinically&#xD;
             significant conditions;&#xD;
&#xD;
          -  12-lead electrocardiogram (ECG) with clinically significant abnormality;acute&#xD;
             infection within 2 weeks preceding 1st study drug administration;any medication on a&#xD;
             regular basis (exception females: oral contraceptives) and/or tricyclic&#xD;
             antidepressants, antacids, histamine H2-receptor antagonists, antibiotics,&#xD;
&#xD;
          -  non steroid anti-inflammatory drugs or anticoagulants within 8 weeks before the 1st&#xD;
             study drug administration and/or no agreement to take any of those drugs including&#xD;
             Over-the-counter (OTC) drugs until the end of the follow- up examination;&#xD;
&#xD;
          -  no agreement not to take any medication,including OTC medicine, antacids, or&#xD;
             analgesics within 2 weeks before 1st drug administration until the end of the&#xD;
             follow-up examination;special diet or loss of &gt; 5 kg within last month from a weight&#xD;
             reduction diet; regularly consume of large quantities of alcohol (&gt; 20g/day) and/or&#xD;
             beverages containing methylxanthines e.g. caffeine (&gt; 0.5L/day altogether);&#xD;
&#xD;
          -  no agreement not to consume: - any beverages or foods containing alcohol 48 h prior to&#xD;
             1st study drug administration until end of the follow-up examination;&#xD;
&#xD;
          -  any grapefruit products 7 days prior 1st study drug administration until end of the&#xD;
             follow-up examination,&#xD;
&#xD;
          -  any beverages or foods containing methylxanthines as well as fruit-juices and any&#xD;
             foods containing poppy seed 48 h before 1st drug administration of either study period&#xD;
             until last blood sample of the respective study period was collected,&#xD;
&#xD;
          -  not to consume chewing during confinement;&#xD;
&#xD;
          -  history of: - allergy to flucloxacillin,&#xD;
&#xD;
          -  B-lactams and/or related drugs,&#xD;
&#xD;
          -  known hypersensitivity against the inactive ingredients of the study medication,&#xD;
&#xD;
          -  hypersensitivity to multiple drugs,&#xD;
&#xD;
          -  allergic diseases,&#xD;
&#xD;
          -  acute hay fever,&#xD;
&#xD;
          -  previous history of flucloxacillin-associated jaundice/hepatic dysfunction,&#xD;
&#xD;
          -  alcohol or drug abuse,&#xD;
&#xD;
          -  epilepsy or other seizure,&#xD;
&#xD;
          -  psychiatric illness, e.g. latent or manifest depression schizophrenia, or neurosis,&#xD;
&#xD;
          -  respiratory diseases,&#xD;
&#xD;
          -  surgery of the gastrointestinal tract (except appendectomy),&#xD;
&#xD;
          -  kidney diseases,&#xD;
&#xD;
          -  bleeding/coagulation disorder or severe anaemia,&#xD;
&#xD;
          -  glucose-6-phosphate dehydrogenase deficiency and/or chronic treatment or chronic&#xD;
             pathology;&#xD;
&#xD;
          -  metabolic disease;&#xD;
&#xD;
          -  evidence for disorder in the metabolism of pharmaceuticals or other foreign compounds;&#xD;
             cardiovascular diseases e.g. hypertension, hypotension or bradycardia;&#xD;
&#xD;
          -  associated disease that would interfere with the clinical course of the trial;&#xD;
&#xD;
          -  major illness during 3 month before commencement of the screening period,&#xD;
&#xD;
          -  gastrointestinal diseases;&#xD;
&#xD;
          -  reported or positive results from test of drugs of abuse (amphetamines, opiates,&#xD;
             barbiturate, methadone, cannabinoids, cocaine, benzodiazepines);&#xD;
&#xD;
          -  Positive test for: alcohol, Hepatitis-B-antigen or Hepatitis-C-antibody,&#xD;
             HIV-antibody;blood donor or blood loss including plasmapheresis within the last 3&#xD;
             months before the 1st study drug administration;&#xD;
&#xD;
          -  intake of depot injectable solutions (including study medication) within 6 month&#xD;
             before 1st study administration;&#xD;
&#xD;
          -  intake of enzyme-inducing and/or organotoxic drugs within 4 weeks before 1st study&#xD;
             drug administration;for females only: positive results from pregnancy tests;does not&#xD;
             use or not agree to use adequate contraceptive methods during the study;&#xD;
&#xD;
          -  lactating woman.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Greifswald</city>
        <state>Mecklenburg-Vorpommern</state>
        <zip>17487</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>September 2017</verification_date>
  <study_first_submitted>July 27, 2006</study_first_submitted>
  <study_first_submitted_qc>July 27, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 31, 2006</study_first_posted>
  <last_update_submitted>September 27, 2017</last_update_submitted>
  <last_update_submitted_qc>September 27, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 29, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>bioavailability flucloxacillin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bacterial Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Floxacillin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

